Literature DB >> 30392803

Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.

Sharon W Kwan1, Stephen K Allison2, Laura S Gold3, David S Shin4.   

Abstract

PURPOSE: To compare relative cost-effectiveness of serial large-volume paracentesis (LVP) and transjugular intrahepatic portosystemic shunt (TIPS) creation for treatment of refractory ascites.
MATERIALS AND METHODS: A decisional Markov model was developed to estimate payer cost and quality-adjusted life-ears (QALYs) associated with LVP and TIPS treatment strategies for cirrhotic patients with refractory ascites. Survival estimates were derived from an individual patient-level meta-analysis of prospective randomized clinical trials. Health utilities for potential health states were derived from a prospective study of patients with cirrhosis. Cost data were derived from national representative claims databases (MarketScan and Medicare) and included reimbursement amounts for relevant procedures, hospitalizations, and outpatient pharmaceutical costs. One-way and probabilistic sensitivity analyses were performed.
RESULTS: LVP resulted in 1.72 QALYs gained at a cost of $41,391, whereas TIPS resulted in 2.76 QALYs gained at a cost of $100,538. Incremental cost-effectiveness ratio of TIPS versus LVP was $57,003/QALY. At a willingness-to-pay ratio of $100,000/QALY, TIPS has a 62% probability of being acceptable compared with LVP.
CONCLUSIONS: This study suggests that TIPS should be considered cost-effective in a country that places a relatively high value on health improvements but less so in countries with lower levels of health care resources. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30392803      PMCID: PMC6334842          DOI: 10.1016/j.jvir.2018.08.019

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  17 in total

1.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.

Authors:  Francesco Salerno; Calogero Cammà; Marco Enea; Martin Rössle; Florence Wong
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

Review 2.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

3.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Authors:  Peter J Neumann; Joshua T Cohen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

4.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

5.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.

Authors:  Pere Ginès; Juan Uriz; Blas Calahorra; Guadalupe Garcia-Tsao; Patrick S Kamath; Luis Ruiz Del Arbol; Ramón Planas; Jaime Bosch; Vicente Arroyo; Juan Rodés
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

6.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

7.  Predicting an SF-6D preference-based score using MCS and PCS scores from the SF-12 or SF-36.

Authors:  Janel Hanmer
Journal:  Value Health       Date:  2009-03-24       Impact factor: 5.725

8.  Interpreting the results of cost-effectiveness studies.

Authors:  David J Cohen; Matthew R Reynolds
Journal:  J Am Coll Cardiol       Date:  2008-12-16       Impact factor: 24.094

9.  Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.

Authors:  Francesco Salerno; Manuela Merli; Oliviero Riggio; Massimo Cazzaniga; Valentina Valeriano; Massimo Pozzi; Antonio Nicolini; Filippo Salvatori
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

10.  Improved curve fits to summary survival data: application to economic evaluation of health technologies.

Authors:  Martin W Hoyle; William Henley
Journal:  BMC Med Res Methodol       Date:  2011-10-10       Impact factor: 4.615

View more
  1 in total

Review 1.  TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis-A case series and review of the literature.

Authors:  Tamara Nordmann; Stefan Schlabe; Torsten Feldt; Federico Gobbi; Andreas Krieg; Johannes G Bode; Andre Fuchs; Christian Kraef; Michael Praktiknjo; Jonel Trebicka; Michael Ramharter; Marylyn M Addo; Christian Strassburg; Ansgar W Lohse; Tom Luedde; Stefan Schmiedel; Hans Martin Orth
Journal:  PLoS Negl Trop Dis       Date:  2021-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.